Cargando…
Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives
The entire spectrum of nonalcoholic fatty liver disease (NAFLD) ranging from fatty liver to cirrhosis has been considered as the result of specific metabolic pathways and mediators, gut barrier function alterations and inflammatory responses. Previous studies have associated intestinal microbiota wi...
Autores principales: | Fotis, Dimitrios, Liu, Junli, Dalamaga, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927988/ https://www.ncbi.nlm.nih.gov/pubmed/35308892 http://dx.doi.org/10.1016/j.metop.2022.100178 |
Ejemplares similares
-
Gut mycobiome as a promising preventive and therapeutic target for metabolic disorders
por: Dalamaga, Maria, et al.
Publicado: (2022) -
Mycobiome and Cancer: What Is the Evidence?
por: Vallianou, Natalia, et al.
Publicado: (2021) -
Could exercise hormone irisin be a therapeutic agent against Parkinson’s and other neurodegenerative diseases?
por: Avgerinos, Konstantinos I., et al.
Publicado: (2023) -
DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH
por: Dalamaga, Maria, et al.
Publicado: (2021) -
Could hyperglycemia-induced cardiac autoimmunity be hidden behind cardiovascular disease in type 1 diabetes mellitus?
por: Vallianou, Natalia, et al.
Publicado: (2019)